Although much work has focused on the elucidation of somatic alterations that drive the
development of acute leukaemias and other haematopoietic diseases, it has become …

The last decade has witnessed great advances in our understanding of the genetic and
biological basis of childhood acute lymphoblastic leukemia (ALL), the development of …

We conducted integrative somatic–germline analyses by deeply sequencing 864 cancer-
associated genes, complete genomes and transcriptomes for 300 mostly previously treated …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy
characterized by aberrant proliferation of immature thymocytes. Despite an overall survival …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and constitutes
approximately 25% of cancer diagnoses among children under the age of 15 (Howlader et …

Disease recurrence causes significant mortality in B-progenitor acute lymphoblastic
leukemia (B-ALL). Genomic analysis of matched diagnosis and relapse samples shows …

Relapsed pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains one of the leading
causes of cancer mortality in children. We performed Hi-C, ATAC-seq, and RNA-seq on 12 …

Purpose: The purpose of the study was to design a pan-cancer gene panel for childhood
malignancies and validate it using clinically characterized patient samples. Experimental …

Chemotherapy is a standard treatment for pediatric acute lymphoblastic leukemia (ALL),
which sometimes relapses with chemoresistant features. However, whether acquired drug …

Chemotherapeutic agents have been used for the treatment of numerous cancers, but due to
poor selectivity and severe systemic side effects, their clinical application is limited. Single …